Drug
Sacituzumab Govitecan
Sacituzumab Govitecan: highest development phase Phase 3, developed by Gilead Sciences, Y-mAbs Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Gilead Sciences, Y-mAbs Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sacituzumab govitecan NCT05552001 | Phase 3 | Triple Negative Breast Cancer |
| Sacituzumab govitecan NCT07011654 | Phase 1/2 | Metastatic Triple-Negative Breast Cancer |
Latest
No recent events.
Follow Sacituzumab Govitecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.